# A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

> **NCT02614794** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 612 (actual)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** tucatinib
- **DRUG:** capecitabine
- **DRUG:** trastuzumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02614794
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-28
- **Primary completion:** 2019-09-04
- **Final completion:** 2022-08-11
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614794, "A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02614794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*